Form 4: Editas Medicine EVP Erick Lucera Reports Share Sale to Cover Tax Obligations

Erick Lucera, EVP and CFO of Editas Medicine, sold 4,109 shares of common stock on March 4, 2025, to cover tax obligations arising from vesting restricted stock units.

Summary

• Erick Lucera, the EVP and CFO of Editas Medicine, filed a Form 4 with the SEC on March 5, 2025.
• The form reports a sale of 4,109 shares of Editas Medicine common stock on March 4, 2025.
• The sale was executed at a weighted average price of $1.7108 per share, with individual trades ranging from $1.7107 to $1.7150.
• The transaction was conducted under a pre-existing automatic sales plan adopted on May 12, 2023.
• The sale was necessary to cover tax withholding obligations related to the vesting of restricted stock units on March 3, 2025.
• Following the reported transaction, Lucera beneficially owns 112,720 shares of Editas Medicine common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common reason for such transactions.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the explanation provided mitigates this concern.

Key Dates